Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Average Rating of “Reduce” by Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been assigned a consensus recommendation of “Reduce” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $16.8333.

A number of equities analysts have commented on IART shares. Citigroup reaffirmed a “sell” rating and issued a $12.00 price objective (up previously from $10.00) on shares of Integra LifeSciences in a report on Tuesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Integra LifeSciences in a research note on Wednesday.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $14.16 on Friday. The company has a market cap of $1.10 billion, a PE ratio of -2.17 and a beta of 1.21. The company has a fifty day moving average price of $14.31 and a two-hundred day moving average price of $14.44. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. Integra LifeSciences has a 12 month low of $11.06 and a 12 month high of $27.13.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The firm had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm’s revenue was down .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its stake in Integra LifeSciences by 55.3% in the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after buying an additional 913 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Integra LifeSciences by 205.9% in the second quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock valued at $38,000 after buying an additional 2,108 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares during the last quarter. AlphaQuest LLC bought a new stake in Integra LifeSciences in the second quarter valued at $73,000. Finally, EMC Capital Management bought a new stake in Integra LifeSciences in the second quarter valued at $75,000. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.